A high speed production line of insulin is pictured at the factory of Novo Nordisk, a global healthcare company, on February 17, 2014, in Chartres.The Danish company, is a world leader in diabetes care and employs, in Chartres, 950 employees. AFP PHOTO/JEAN-FRANCOIS MONIER (Photo credit should read JEAN-FRANCOIS MONIER/AFP/Getty Images)Photograph by Jean-Francois Monier — AFP/Getty Images
In 1994, few of China’s legions of diabetics—the nation has 96.3 million today compared with 26 million in the U.S.—received regular insulin treatments. That’s when Danish drugmaker Novo Nordisk committed to tackling diabetes in China—an effort that involved training tens of thousands of physicians, educating patients, and investing in local manufacturing and R&D. The results? A 2011 research paper estimated that the efforts had saved 140,000 life-years from diabetes-related complications. Novo, meanwhile, has a 63% market share in China.
Company Info
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Country | Denmark |
| Revenues ($ millions) | 15,802 |
| Company type | Public |
| CEO | Lars Rebien Sørensen |
| Website | www.novonordisk.com |
| Impact Segment | Public Health/Nutrition |
Fortune Rankings
| Fortune 500 Rank | - |
| Fortune 500 Profile | - |
| Most Powerful Women Rank | - |
| Most Powerful Women Profile | - |
| World's Greatest Leaders Rank | - |
| World's Greatest Leaders Profile | - |